Jose Zuniga
Neurology · West Palm Beach, FLNPI 1679675813
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.4% of the total across 525 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 6.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $3,598 and has fallen 64.0% since, to $1,294 in 2025.
Across 525 payments — averaging $26.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$954
- Sanofi$944
- EMD Serono, Inc.$938
- AbbVie$930
- Merck$858
- ANI Pharmaceuticals, Inc.$810
- plus $8K from 50 others
Across 29 payments — averaging $14,835 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$265K
- Avanir Pharmaceuticals, Inc.$104K
- Janssen Research & Development, LLC$62K
What the payments were for
- Consulting fees$8586%
- Food & beverage$12,86792%
- Education$2011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PURIFIED CORTROPHIN GEL$783
- APOKYN$739
- REXULTI$372
- ZEPOSIA$245
- AUSTEDO$237
- Mavenclad$230
- AUBAGIO$167
- ENROUTE Transcarotid Neuroprotection System$152
- ENROUTE Transcarotid Stent System$152
- ENHANCE Transcarotid Peripheral Access Kit$152
- ENROUTE 0.014 Guidewire$152
- ACTHAR$127
- NUPLAZID$125
- NUEDEXTA$122
- ULTOMIRIS$122
- SPINRAZA$122
How this compares
$13,925 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 22 | $545 |
| Gabapentin | 12 | $334 |
| Clonazepam | 12 | $15 |
Paid to pharmacies, not to this prescriber.
Other neurology in West Palm Beach
- Nisha ChhabriaWest Palm Beach$182K
- Arnaldo da SilvaWest Palm Beach$138K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.